Amsterdam, 7 May 2021 (dpa/MIA) – The European Medicines Agency (EMA) has launched a review of a drug to treat Covid-19 patients.
Study results of the antibody drug sotrovimab will be assessed under the accelerated rolling review procedure, the EMA announced in Amsterdam on Friday.
The drug is produced by the British manufacturer GlaxoSmithKline together with the US company Vir Biotechnology.
According to the EMA, initial results of studies indicate that the drug could prevent a severe bout of the Covid-19 disease and thus hospitalization and death.
However, since the EMA has not yet received all the data, it is not yet possible to weigh up the benefits and risks. It is unclear how long the review will take.
In the rolling review process, data are assessed even before the studies have been completed, and an application for marketing authorization has already been submitted.
The EMA experts are already reviewing three other antibody drugs against Covid-19. So far, remdesivir is the only drug that the agency has approved for the treatment of Covid-19.